DE60029948D1 - Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut - Google Patents

Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut

Info

Publication number
DE60029948D1
DE60029948D1 DE60029948T DE60029948T DE60029948D1 DE 60029948 D1 DE60029948 D1 DE 60029948D1 DE 60029948 T DE60029948 T DE 60029948T DE 60029948 T DE60029948 T DE 60029948T DE 60029948 D1 DE60029948 D1 DE 60029948D1
Authority
DE
Germany
Prior art keywords
mammalian blood
subject
treatment
improved method
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60029948T
Other languages
English (en)
Inventor
Anthony E Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DE60029948D1 publication Critical patent/DE60029948D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/13—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/369—Temperature treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
    • A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60029948T 1999-05-06 2000-05-08 Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut Expired - Lifetime DE60029948D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002271190A CA2271190A1 (en) 1999-05-06 1999-05-06 Improved method for treating mammals with modified mammalian blood
PCT/CA2000/000566 WO2000067764A2 (en) 1999-05-06 2000-05-08 Improved method for treating mammals with modified mammalian blood

Publications (1)

Publication Number Publication Date
DE60029948D1 true DE60029948D1 (de) 2006-09-21

Family

ID=4163523

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60029948T Expired - Lifetime DE60029948D1 (de) 1999-05-06 2000-05-08 Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut

Country Status (7)

Country Link
US (2) US6986888B1 (de)
EP (1) EP1181026B1 (de)
AT (1) ATE335497T1 (de)
AU (1) AU4738500A (de)
CA (1) CA2271190A1 (de)
DE (1) DE60029948D1 (de)
WO (1) WO2000067764A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045124B1 (en) 1999-01-12 2006-05-16 Vasogen Irelend Limited Pre-conditioning against cell death
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2327630A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Transforming growth factor regulation
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
WO2005097145A1 (en) * 2004-04-12 2005-10-20 Vasogen Ireland Limited Myocarditis treatment
EP1773360A4 (de) * 2004-07-20 2009-09-02 Vasogen Ireland Ltd Behandlung von akuten entzündlichen zuständen
CA2765479A1 (en) * 2009-06-19 2010-12-23 Acquisci, Inc. Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
CA2856235A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters of dcpla for the treatment of neurodegenerative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8704467U1 (de) 1987-01-15 1988-05-26 Quarzlampenfabrik Dr.-Ing. Felix W. Müller GmbH & Co KG, 45239 Essen Gerät zur Herstellung von oxygeniertem Blut
EP1243278B1 (de) 1992-02-07 2007-01-03 Vasogen Ireland Limited Verwendung von Blut mit erhöhter Stickoxidkonzentration zur Herstellung eines Medikaments
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US5591457A (en) 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
DK0768886T3 (da) 1995-05-05 2003-12-01 Vasogen Ireland Ltd Endothelforingseffekter og behandling af vasospastiske lidelser
US6136308A (en) * 1997-09-12 2000-10-24 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
ES2210814T3 (es) 1997-09-12 2004-07-01 Vasogen Ireland Limited Tratamiento del estres y acondicionamiento previo contra el estres.
NZ511467A (en) 1998-11-13 2002-12-20 Vasogen Ireland Ltd Method for preventing and reversing atherosclerosis in mammals
CA2269364A1 (en) 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure

Also Published As

Publication number Publication date
US20050238623A1 (en) 2005-10-27
AU4738500A (en) 2000-11-21
US6986888B1 (en) 2006-01-17
WO2000067764A2 (en) 2000-11-16
US7223391B2 (en) 2007-05-29
ATE335497T1 (de) 2006-09-15
EP1181026B1 (de) 2006-08-09
EP1181026A2 (de) 2002-02-27
CA2271190A1 (en) 2000-11-06
WO2000067764A3 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
ATE281840T1 (de) Behandlung von diarrhoe
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
ATE155043T1 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE60029948D1 (de) Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut
ATE289508T1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE254924T1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
NO955258L (no) Medisinsk anvendelse av enzymer
ATE141053T1 (de) Verwendung von torasemid zur behandlung von hirnödemen
ATE245991T1 (de) Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin
ATE31022T1 (de) Verwendung von 4,5'-azo-bis-salicylsaeure zur herstellung eines arzneimittels zur behandlung entzuendlicher darmkrankheiten.
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden

Legal Events

Date Code Title Description
8332 No legal effect for de